Michael Schmitz
Stock Analyst at Guggenheim
(1.31)
# 3,340
Out of 4,711 analysts
15
Total ratings
42.86%
Success rate
-2.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $44.06 | +86.11% | 2 | Oct 28, 2024 | |
| MRUS Merus | Maintains: Buy | $93 → $111 | $41.85 | +165.23% | 2 | Oct 1, 2024 | |
| BPMC Blueprint Medicines | Maintains: Buy | $130 → $138 | $90.14 | +53.10% | 8 | Aug 2, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $18.48 | +116.45% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.68 | - | 1 | Jan 3, 2023 | |
| NOVA Sunnova Energy International | Initiates: Buy | $15 | $3.70 | +305.41% | 1 | Jan 6, 2020 |
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $44.06
Upside: +86.11%
Merus
Oct 1, 2024
Maintains: Buy
Price Target: $93 → $111
Current: $41.85
Upside: +165.23%
Blueprint Medicines
Aug 2, 2024
Maintains: Buy
Price Target: $130 → $138
Current: $90.14
Upside: +53.10%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $18.48
Upside: +116.45%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.68
Upside: -
Sunnova Energy International
Jan 6, 2020
Initiates: Buy
Price Target: $15
Current: $3.70
Upside: +305.41%